Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Noul Co. Ltd. has a patent portfolio within the Biotechnology & Pharmaceuticals technology area. There are currently 2 pending office actions under review. These actions are spread across 2 distinct examiners and 2 distinct art units, showing no overlap in the personnel or units reviewing the company's biotechnology applications.
KELLY, ROBERT M is identified as the busiest examiner, with 1 busiest examiner pending action. Since the total count of pending office actions is 2, the workload is evenly divided among the 2 distinct examiners. This structure requires the applicant to manage two separate prosecution tracks, each subject to the different standards of two distinct art units. This lack of concentration in the biotechnology sector means that the company must be prepared for potentially divergent feedback from different technical groups within the office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KELLY, ROBERT M | 1 | 74.1% | +24.1% |
| MARCHESCHI, MICHAEL A | 1 | 20.0% | +17.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18855706 | FIXATIVE COMPOSITION FOR PREPARING SMEAR SPECIMENS OF BIOLOGICAL SAMPLES | KELLY, ROBERT M | — |
| 17322803 | CULTURING PATCH, CULTURING METHOD, CULTURE TEST METHOD, CULTURE TEST DEVICE, DRUG TEST METHOD, AND DRUG TEST DEVICE | MARCHESCHI, MICHAEL A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18855706 | FIXATIVE COMPOSITION FOR PREPARING SMEAR SPECIMENS OF BIOLOGICAL SAMPLES | KELLY, ROBERT M | — |
| 17322803 | CULTURING PATCH, CULTURING METHOD, CULTURE TEST METHOD, CULTURE TEST DEVICE, DRUG TEST METHOD, AND DRUG TEST DEVICE | MARCHESCHI, MICHAEL A | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1796 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18855706 | FIXATIVE COMPOSITION FOR PREPARING SMEAR SPECIMENS OF BIOLOGICAL SAMPLES | KELLY, ROBERT M | 1638 | §102§112 | Non-Final OA | — | Pending | Oct 10, 2024 |
| 17322803 | CULTURING PATCH, CULTURING METHOD, CULTURE TEST METHOD, CULTURE TEST DEVICE, DRUG TEST METHOD, AND DRUG TEST DEVICE | MARCHESCHI, MICHAEL A | 1796 | §102 | Non-Final OA | — | Pending | May 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNoul Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Robert M Kelly has the most, with 1 of Noul Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
